

a station and will be used by the Commission to verify that licensees are fully coordinated with other users in the band. The information collected is used to determine whether the public interest, convenience and necessity will be served.

OMB Approval Number: 3060-XXXX.

Title: Aeronautical Services Transition Plan.

Form No.: N/A.

Type of Review: New Collection.

Respondents: Business or other for-profit.

Number of Respondents: 6.

Estimated Time Per Response: 2 hours.

Total Annual Burden: 12 hours.

Total Costs to all Respondents: \$5,400. This is based on the assumption that applicants will hire outside counsel at an approximate cost of \$150 per hour, for six hours. It is estimated that the cost per submission will be \$900.

Needs and Uses: On April 9, 1996 the Commission adopted Order on Reconsideration and Further Notice of Proposed Rulemaking, 61 FR 30579. When AMSS becomes available on the domestic satellite, current AMSS users will be transitioning from Inmarsat to the domestic provider. To ensure the continuity of service during the transition from Inmarsat to the U.S. domestic AMSS licensee, the Commission adopted a requirement that operators providing interim domestic Aeronautical mobile satellite services (AMSS) via Inmarsat file a transition plan as operations are moved to the U.S. domestic licensee. The information collection will be used by the Commission and the domestic licensee to ensure technical feasibility of the transition and continuity of service as the U.S. Domestic licensee begins to provide domestic AMSS.

OMB Approval Number: 3060-XXXX.

Title: Price Cap Performance Review for Local Exchange Carriers, CC Docket No. 94-1.

Form No.: N/A.

Type of Review: New Collection.

Respondents: Business or other for-profit.

Number of Respondents: 13 with approximately 2 responses annually.

Estimated Time Per Response: 5 hours.

Total Annual Burden: 130 hours.

Total Costs to all Respondents: \$0.

Needs and Uses: In the Third Report and Order issued in CC Docket 94-1, the Commission modified its filing requirement for incumbent price cap Local Exchange Carriers (LECs) who propose to offer new switched access services. We no longer require an

incumbent LEC to introduce a new service by filing a waiver under Part 69 of the Commission's rules. Instead, incumbent LECs will be able to file a petition for the lower service band indices in the proceeding. By doing so, an incumbent price cap LEC no longer has to file a waiver to set its rates below the lower service band indices, but instead may simply adjust its rates downward.

Federal Communications Commission

Shirley S. Suggs,

Chief, Publications Branch.

[FR Doc. 97-10673 Filed 4-24-97; 8:45 am]

BILLING CODE 6712-01-P

FEDERAL DEPOSIT INSURANCE CORPORATION

Sunshine Act Meeting

Pursuant to the provisions of the "Government in the Sunshine Act" (5 U.S.C. 552b), notice is hereby given that the Federal Deposit Insurance Corporation's Board of Directors will meet in open session at 10:00 a.m. on Tuesday, April 29, 1997, to consider the following matters:

Summary Agenda: No substantive discussion of the following items is anticipated. These matters will be resolved with a single vote unless a member of the Board of Directors requests that an item be moved to the discussion agenda.

Disposition of minutes of previous

Board of Directors' meetings.

Reports of actions taken pursuant to authority delegated by the Board of Directors.

Memorandum and resolution re: Proposed Amendments to Part 307—Notification of Changes of Insured Status.

Memorandum and resolution re: Statement of Policy on Interagency Notification and Coordination of Enforcement Actions by the Federal Banking Regulatory Agencies.

Memorandum and resolution re: Rescission of Uniform Guideline on Internal Control for Foreign Exchange Activities in Commercial Banks.

Memorandum and resolution re: Rescission of Statement of Policy on Changes in Control in Insured Nonmember Banks.

Memorandum and resolution re: Proposed Rescission of Part 343—Insured State Nonmember Banks which are Municipal Securities Dealers.

Discussion Agenda

Corporation's Strategic Plan.

Memorandum and resolution re:

Proposed Rule Regarding Deposit Insurance Simplification.

Memorandum and resolution re:

Rescission of Statement of Policy on Assistance to Operating Insured Depository Institutions.

The meeting will be held in the Board Room on the sixth floor of the FDIC Building located at 550—17th Street, N.W., Washington, D.C.

The FDIC will provide attendees with auxiliary aids (e.g., sign language interpretation) required for this meeting. Those attendees needing such assistance should call (202) 416-2449 (Voice); (202) 416-2004 (TTY), to make necessary arrangements.

Requests for further information concerning the meeting may be directed to Mr. Robert E. Feldman, Deputy Executive Secretary of the Corporation, at (202) 898-6757.

Dated: April 22, 1997.

Federal Deposit Insurance Corporation

Robert E. Feldman,

Deputy Executive Secretary.

[FR Doc. 97-10836 Filed 4-23-97; 10:30 am]

BILLING CODE 6714-01-M

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act. Unless otherwise noted, nonbanking

activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than May 19, 1997.

A. Federal Reserve Bank of Philadelphia (Michael E. Collins, Senior Vice President) 100 North 6th Street, Philadelphia, Pennsylvania 19105-1521; 1. *Susquehanna Bancshares, Inc.* Lititz, Pennsylvania; to acquire 100 percent of the voting shares of Founders Bank, Bryn Mawr, Pennsylvania.

B. Federal Reserve Bank of St. Louis (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63102-2034;

1. *First Robinson Financial Corporation*, Robinson, Illinois; to become a bank holding company by acquiring 100 percent of the voting shares of First Robinson Savings Bank, National Association, Robinson, Illinois, the successor to the charter of First Robinsin Savings & Loan, F.A., Robinson, Illinois, which will convert from a mutual to a stock savings and loan association, and then to a national bank.

Board of Governors of the Federal Reserve System, April 21, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97-10691 Filed 4-24-97; 8:45 am]

BILLING CODE 6210-01-F

FEDERAL RESERVE SYSTEM

Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y, (12 CFR Part 225) to engage *de novo*, or to acquire or control voting securities or assets of a company that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. Once the notice has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may

express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than May 9, 1997.

A. Federal Reserve Bank of Minneapolis (Karen L. Grandstrand, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480-2171:

1. *Norwest Corporation*, Minneapolis, Minnesota; to acquire IMS Mortgage Company, Cedar Rapids, Iowa, and thereby engage in residential mortgage lending activities, pursuant to § 225.28(b)(1) of the Board's Regulation Y. The co-venturers will be Norwest Ventures, Inc., Des Moines, Iowa, and East Brook Corporation of Iowa, d/b/a/ Skogman Realty, Cedar Rapids, Iowa.

Board of Governors of the Federal Reserve System, April 21, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97-10690 Filed 4-24-97; 8:45 am]

BILLING CODE 6210-01-F

FEDERAL RESERVE SYSTEM

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Board of Governors of the Federal Reserve System.

FEDERAL REGISTER CITATION OF PREVIOUS ANNOUNCEMENT: 62 FR 18629-30, April 16, 1997.

PREVIOUSLY ANNOUNCED TIME AND DATE OF THE MEETING: 11:00 a.m., Monday, April 21, 1997.

CHANGES IN THE MEETING: Addition of the following closed items to the meeting: (1) Proposed amendments to the Voluntary Guide to Conduct for Senior Federal Reserve System Officials; and (2) Status Report of the Committee on the Federal Reserve in the Payments Mechanism (Alternative Roles for the Federal Reserve in the Retail Payments System).

CONTACT PERSON FOR MORE INFORMATION: Mr. Joseph R. Coyne, Assistant to the Board; (202) 452-3204.

Dated: April 22, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97-10824 Filed 4-23-97; 10:30 am]

BILLING CODE 6210-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97N-0137]

Cellpro, Inc.; Premarket Approval of CEPRATE® SC Stem Cell Concentration System

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing its approval of the application by CellPro, Inc., Bothell, WA, for premarket approval, under the Federal Food, Drug, and Cosmetic Act (the act), of the CEPRATE® SC Stem Cell Concentration System (CEPRATE® SC System). FDA's Center for Biologics Evaluation and Research (CBER) notified the applicant, by letter of December 6, 1996, of the approval of the application.

DATES: Petitions for administrative review by May 27, 1997.Q02

ADDRESSES: Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Keith O. Webber, Center for Biologics Evaluation and Research (HFM-594), 1401 Rockville Pike, Rockville, MD 20852-1448, 301-827-5103.

SUPPLEMENTARY INFORMATION: On January 3, 1994, CellPro, Inc., Bothell, WA 98021, submitted to CBER an application for premarket approval of the CEPRATE® SC System. The device is indicated for the processing of autologous bone marrow to obtain a cell population enriched with cells displaying the CD34 surface marker (CD34+). Such cells are intended for hematopoietic support after myeloablative chemotherapy. Infusion of CD34+ enriched cell populations results in a lower incidence of dimethyl sulfoxide infusion-associated complications compared with infusion of unselected bone marrow cells. The CEPRATE® SC System consists of an instrument and a single-use, sterile, prepackaged kit containing disposable components which includes: (1) An avidin column, (2) a precolumn, (3) a tubing set, (4) a vial of anti-CD34+ biotinylated monoclonal antibody, (5) a blood filter, and (6) wash and culture media. The CEPRATE® SC System concentrates CD34+ cells using a